Decreased expression of chromodomain helicase DNA-binding protein 5 is an unfavorable prognostic marker in patients with primary gallbladder carcinoma

Clinical and Translational Oncology

Volumn 15, Issue 3, 2013, Pages 198-204

  Du, Xilin ^a   Wu, Tao ^a   Lu, Jianguo ^a   Zang, Li ^a   Song, Nuan ^a   Yang, Tao ^a   Zhao, Huadong ^a   Wang, Shengzhi ^a  

^a FOURTH MILITARY MEDICAL UNIVERSITY   (China)

Author keywords

Chromodomain helicase DNA binding protein 5; Clinicopathology; Disease free survival; Overall survival; Primary gallbladder carcinoma

Indexed keywords

CHROMODOMAIN HELICASE DNA BINDING PROTEIN 5; DNA BINDING PROTEIN; MESSENGER RNA; UNCLASSIFIED DRUG;

AGED; ARTICLE; CANCER PROGNOSIS; CANCER STAGING; CANCER SURVIVAL; CARCINOGENESIS; CHROMODOMAIN HELICASE DNA BINDING PROTEIN 5 GENE; CONTROLLED STUDY; DISEASE ASSOCIATION; DISEASE FREE SURVIVAL; FEMALE; GALLBLADDER CARCINOMA; GENE; GENE EXPRESSION; HUMAN; HUMAN TISSUE; MAJOR CLINICAL STUDY; MALE; OVERALL SURVIVAL; PRIMARY GALLBLADDER CARCINOMA; PROTEIN EXPRESSION; QUANTITATIVE ANALYSIS; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; WESTERN BLOTTING;

EID: 84878525841     PISSN: 1699048X     EISSN: 16993055     Source Type: Journal    
DOI: 10.1007/s12094-012-0903-2     Document Type: Article

References (26)

1. Puhalla H, Wrba F, Kandioler D, Lehnert M, Huynh A, Gruenberger T, Tamandl D, Filipits M (2007) Expression of p21(Wafl/Cip1), p57(Kip2) and HER2/neu in patients with gallbladder cancer. Anticancer Res 27:1679-1684
2. Roa I, de Aretxabala X, Lantadilla S, Munoz S (2011) ERCC1 (excision repair cross-complementing 1) expression in pT2 gallbladder cancer is a prognostic factor. Histol Histopathol 26:37-43
3. Chen Y, Chen Y, Yu G, Ding H (2011) Lymphangiogenic and angiogentic microvessel density in gallbladder carcinoma. Hepatogastroenterology 58:20-25
4. Misra S, Chaturvedi A, Misra NC (2003) Carcinoma of the gallbladder. Lancet Oncol 4:167-176
5. Ando A, Suzuki C (2005) Cooperative function of the CHD5-like protein Mdm39p with a P-type ATPase Spf1p in the maintenance of ER homeostasis in Saccharomyces cerevisiae. Mol Genet Genomics 273:497-506
6. Yoshimura S, Yoshimi T, Ohkawa Y, Azuma M, Tachibana T (2010) A rat monoclonal antibody against the chromatin remodeling factor CHD5. Hybridoma (Larchmt) 29:63-66
7. Potts RC, Zhang P, Wurster AL, Precht P, Mughal MR, Wood WH 3rd, Zhang Y, Becker KG, Mattson MP, Pazin MJ (2011) CHD5, a brain-specific paralog of Mi2 chromatin remodeling enzymes, regulates expression of neuronal genes. PLoS One 6:e24515
8. Thompson PM, Gotoh T, Kok M, White PS, Brodeur GM (2003) CHD5, a new member of the chromodomain gene family, is preferentially expressed in the nervous system. Oncogene 22:1002-1011
9. Koyama H, Zhuang T, Light JE, Kolla V, Higashi M, McGrady PW, London WB, Brodeur GM (2012) Mechanisms of CHD5 inactivation in neuroblastomas. Clin Cancer Res 18:1588-1597
10. Muthuswamy SK (2009) A new tumor suppressor that regulates tissue architecture. PLoS Med 6:e1000073
11. Law ME, Templeton KL, Kitange G, Smith J, Misra A, Feuerstein BG, Jenkins RB (2005) Molecular cytogenetic analysis of chromosomes 1 and 19 in glioma cell lines. Cancer Genet Cytogenet 160:1-14
12. Mokarram P, Kumar K, Brim H, Naghibalhossaini F, Saberi-firoozi M, Nouraie M, Green R, Lee E, Smoot DT, Ashktorab H (2009) Distinct high-profile methylated genes in colorectal cancer. PLoS One 4:e7012
13. Garcia I, Mayol G, Rodríguez E, Sunol M, Gershon TR, Ríos J, Cheung NK, Kieran MW, George RE, Perez-Atayde AR, Casala C, Galván P, de Torres C, Mora J, Lavarino C (2010) Expression of the neuron-specific protein CHD5 is an independent marker of outcome in neuroblastoma. Mol Cancer 9:277
14. Lang J, Tobias ES, Mackie R (2011) Preliminary evidence for involvement of the tumour suppressor gene CHD5 in a family with cutaneous melanoma. Br J Dermatol 164:1010-1016
15. Gorringe KL, Choong DY, Williams LH, Ramakrishna M, Sridhar A, Qiu W, Bearfoot JL, Campbell IG (2008) Mutation and methylation analysis of the chromodomain-helicase-DNA binding 5 gene in ovarian cancer. Neoplasia 10:1253-1258
16. Mulero-Navarro S, Esteller M (2008) Chromatin remodeling factor CHD5 is silenced by promoter CpG island hypermethylation in human cancer. Epigenetics 3:210-215
17. Roh YH, Kim YH, Choi HJ, Lee KE, Roh MS (2008) Syndecan-1 expression in gallbladder cancer and its prognostic significance. Eur Surg Res 41:245-250
18. Alvarez H, Corvalan A, Roa JC, Argani P, Murillo F, Edwards J, Beaty R, Feldmann G, Hong SM, Mullendore M, Roa I, Ibañez L, Pimentel F, Diaz A, Riggins GJ, Maitra A (2008) Serial analysis of gene expression identifies connective tissue growth factor expression as a prognostic biomarker in gallbladder cancer. Clin Cancer Res 14:2631-2638
19. Ng D, Yang XR, Tucker MA, Goldstein AM (2008) Mutation screening of CHD5 in melanoma-prone families linked to 1p36 revealed no deleterious coding or splice site changes. BMC Res Notes 1:86
20. White PS, Thompson PM, Gotoh T, Okawa ER, Igarashi J, Kok M, Winter C, Gregory SG, Hogarty MD, Maris JM, Brodeur GM (2005) Definition and characterization of a region of 1p36.3 consistently deleted in neuroblastoma. Oncogene 24:2684-2694
21. Fujita T, Igarashi J, Okawa ER, Gotoh T, Manne J, Kolla V, Kim J, Zhao H, Pawel BR, London WB, Maris JM, White PS, Brodeur GM (2008) CHD5, a tumor suppressor gene deleted from 1p36.31 in neuroblastomas. J Natl Cancer Inst 100:940-949
22. Bagchi A, Mills AA (2008) The quest for the 1p36 tumor suppressor. Cancer Res 68:2551-2556
23. Wang J, Chen H, Fu S, Xu ZM, Sun KL, Fu WN (2011) The involvement of CHD5 hypermethylation in laryngeal squamous cell carcinoma. Oral Oncol 47:601-608
24. Wang X, Lau KK, So LK, Lam YW (2009) CHD5 is down-regulated through promoter hypermethylation in gastric cancer. J Biomed Sci 16:95
25. Zhao R, Yan Q, Lv J, Huang H, Zheng W, Zhang B, Ma W (2012) CHD5, a tumor suppressor that is epigenetically silenced in lung cancer. Lung Cancer 76(3):324-331
26. Wong RR, Chan LK, Tsang TP, Lee CW, Cheung TH, Yim SF, Siu NS, Lee SN, Yu MY, Chim SS, Wong YF, Chung TK (2011) CHD5 downregulation associated with poor prognosis in epithelial ovarian cancer. Gynecol Obstet Invest 72:203-207